Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB

PHASE3CompletedINTERVENTIONAL
Enrollment

384

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

September 30, 2016

Conditions
Overactive Bladder
Interventions
DRUG

THVD-201

Combination of Tolterodine 2mg and Pilocarpine 9mg

DRUG

Placebo(For THVD-201)

DRUG

Detrusitol 2mg tablet

Tolterodine 2mg

DRUG

Placebo(For Detrusitol 2mg tablet)

Trial Locations (16)

Unknown

Inje University Busan Paik Hospital, Busan

Dankook University Hospital, Cheonan

Chonnam National University Hospital, Gwangju

Pusan National University Hospital, Pusan

Bundang Cha Medical center, Seongnam

Ajou University Medical Center, Seoul

Asan Medical Center, Seoul

Cheil General Hospital, Seoul

Gachon University Gil Medical Center, Seoul

Konkuk University Medical Center, Seoul

Korea University Anam Hospital, Seoul

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

Severance Hospital, Seoul

The Catholic University of Korea, Bucheon ST. Mary's Hospital, Seoul

The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul

All Listed Sponsors
lead

SK Chemicals Co., Ltd.

INDUSTRY

NCT02485067 - Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB | Biotech Hunter | Biotech Hunter